ESR1 and cancer: Two general patterns of endocrine therapy resistance are recognized clinically: primary, intrinsic resistance, whereby estrogen receptor‐expressing (ER‐positive) cancers never adequately respond to endocrine treatment, and secondary, acquired resistance, which develops following an initial response.2